Clinical Trials
212 trialsORCHID
Fudan University
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company
innovaTV 301
Seagen Inc.
ARCADIAN
University of Oxford
CheckMate 816
Bristol-Myers Squibb
PRECIOUS
Japan Breast Cancer Research Group
EORTC1616
The Netherlands Cancer Institute
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
City of Hope Medical Center
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
MOCCCA
Insel Gruppe AG, University Hospital Bern
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
IPSOS
Hoffmann-La Roche
TROPiCS-02
Gilead Sciences
RIGHT Choice
Novartis
PADMA
GBG Forschungs GmbH
ARCTIC
AstraZeneca
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
METEORA-II
ETOP IBCSG Partners Foundation
NORA
Spanish Lung Cancer Group
TULIP
Byondis B.V.
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
University of Nebraska
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
DURATION
AIO-Studien-gGmbH
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
ATTAIN
Nektar Therapeutics
NVB Metro
Assistance Publique Hopitaux De Marseille
Vinorelbine for Recurrent ACLC
Children's Cancer Group, China
ASCENT
Gilead Sciences
NARLAL
Odense University Hospital
VinMetAtezo
University Hospital, Brest
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Children's Oncology Group
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Fudan University
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
KEYNOTE-119
Merck Sharp & Dohme LLC
VIM
Wales Cancer Trials Unit
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Children's Oncology Group
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer
Medstar Health Research Institute
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Jonsson Comprehensive Cancer Center